Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Change in Receivables (2018 - 2025)

Bicycle Therapeutics' Change in Receivables history spans 7 years, with the latest figure at $133000.0 for Q1 2025.

  • For Q1 2025, Change in Receivables changed N/A year-over-year to $133000.0; the TTM value through Mar 2025 reached $170000.0, changed N/A, while the annual FY2023 figure was -$2.5 million, 251.25% down from the prior year.
  • Change in Receivables reached $133000.0 in Q1 2025 per BCYC's latest filing, down from $49.9 million in the prior quarter.
  • In the past five years, Change in Receivables ranged from a high of $49.9 million in Q3 2023 to a low of -$49.8 million in Q2 2023.
  • Average Change in Receivables over 4 years is -$477363.6, with a median of -$991000.0 recorded in 2022.
  • The largest YoY upside for Change in Receivables was 614.5% in 2023 against a maximum downside of 582.14% in 2023.
  • A 4-year view of Change in Receivables shows it stood at $1.0 million in 2021, then skyrocketed by 98.7% to $2.0 million in 2022, then soared by 2407.59% to $49.9 million in 2023, then crashed by 99.73% to $133000.0 in 2025.
  • Per Business Quant, the three most recent readings for BCYC's Change in Receivables are $133000.0 (Q1 2025), $49.9 million (Q3 2023), and -$49.8 million (Q2 2023).